US Bank Maintains Buy Rating on Merus Stock

Summary

Bank of America Securities has maintained a Buy rating on Merus stock with a $92.00 price target, indicating a 42.44% upside from current levels.Tip Ranks

Impact Analysis

So basically, Bank of America Securities is doubling down on Merus despite the usual biotech hurdles—high cash burn and clinical trial dependencies. The interesting part isn’t just the reaffirmed buy rating; it’s the $92 price target, which suggests a significant upside of over 42% from current levels.Tip Ranks This implies that the market might be underestimating Merus’s potential, especially given the positive analyst consensus and interest in its immuno-oncology pipeline.Simplywall However, the stock’s modest price movements indicate that investors are still cautious, likely due to the clinical trial risks and cash requirements.Simplywall The technical analysis shows a strong long-term uptrend, but short-term signals are mixed, suggesting potential volatility. I’d read this as a high-risk, high-reward scenario where the upside could be substantial if Merus successfully navigates its clinical trials. Keep an eye on trial results and cash flow updates—they’re the real swing factors here.